POMGNT1

Across TCGA pan-cancer cohorts, POMGNT1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of POMGNT1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where POMGNT1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types POMGNT1 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where POMGNT1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in POMGNT1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	+0.147	<.001	7	view →
LUAD	Female	II,III,IV	−0.392	<.001	6	view →
HNSC	All	II,III,IV	+0.206	<.001	6	view →
OV	All	All	+0.353	.031	2	view →
LSCC	All	II,III,IV	−0.117	.025	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

POMGNT1–CCRCC

Open the CCRCC breakdown →